Group 1 - The core point of the article is that Kehua Bio has received a medical device registration certificate for its "Human ALDH2 Gene Polymorphism Detection Kit" from the National Medical Products Administration [1] - Kehua Bio's revenue composition for the first half of 2025 is entirely from the biopharmaceutical sector, accounting for 100.0% [1] - As of the report, Kehua Bio has a market capitalization of 3.1 billion yuan [1]